Risk factors for myelosuppression in chronic phase CML patients treated with Imatinib mesylate (STI571).

被引：0
|
作者：
Mauro, MJ
O'Dwyer, ME
Kurilik, G
Blasdel, C
Farnsworth, M
Fong, D
Hsieh, YC
Mori, M
Ford, JM
Druker, BJ
机构：
[1] Oregon Hlth Sci Univ, Leukemia Ctr, Portland, OR 97201 USA
[2] Univ Hong Kong, Clin Trials Ctr, Hong Kong, Hong Kong, Peoples R China
[3] Novartis Pharma, Basel, Switzerland
来源：
BLOOD | 2001年 / 98卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
585
引用
收藏
页码：139A / 139A
页数：1
相关论文
共 50 条
  • [21] Imatinib mesylate (STI571) treatment in patients with chronic-phase chronic myelogenous leukaemia previously submitted to autologous stem cell transplantation
    Cervantes, F
    Hernández-Boluda, JC
    Odriozola, J
    Camós, M
    Villalón, L
    Martínez-Climent, JA
    Del Campo, R
    García-Conde, J
    Montserrat, E
    BRITISH JOURNAL OF HAEMATOLOGY, 2003, 120 (03) : 500 - 504
  • [22] Histologic and cytogenetic relapse and progression in CML patients treated with STI571 (GLEEVEC)
    Hasserjian, RP
    Chase, A
    Dhar, S
    Olavarria, E
    Lampert, I
    Henry, K
    Apperley, JF
    Goldman, JM
    MODERN PATHOLOGY, 2002, 15 (01) : 244A - 244A
  • [23] Histologic and cytogenetic relapse and progression in CML patients treated with STI571 (GLEEVEC)
    Hasserjian, RP
    Chase, A
    Dhar, S
    Olavarria, E
    Lampert, I
    Henry, K
    Apperley, JF
    Goldman, JM
    LABORATORY INVESTIGATION, 2002, 82 (01) : 244A - 244A
  • [24] Effect of rifampicin on the pharmacokinetics of imatinib mesylate (Gleevec, STI571) in healthy subjects
    Bolton, AE
    Peng, B
    Hubert, M
    Krebs-Brown, A
    Capdeville, R
    Keller, U
    Seiberling, M
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2004, 53 (02) : 102 - 106
  • [25] Effect of rifampicin on the pharmacokinetics of imatinib mesylate (Gleevec, STI571) in healthy subjects
    Ann E. Bolton
    Bin Peng
    Martine Hubert
    Axel Krebs-Brown
    Renaud Capdeville
    Urs Keller
    Michael Seiberling
    Cancer Chemotherapy and Pharmacology, 2004, 53 : 102 - 106
  • [26] Chronic myeloid leukemia in a patient with chronic idiopathic thrombocytopenic purpura: Rapid response to imatinib mesylate (STI571)
    Imashuku, S
    Morimoto, A
    Kuriyama, K
    Kano, G
    Hibi, S
    Todo, S
    MEDICAL AND PEDIATRIC ONCOLOGY, 2003, 41 (02): : 159 - +
  • [27] Bone marrow biopsy (BM) morphology in patients with chronic myeloid leukemia (CML) treated with STI571
    Chiu, A
    Silver, R
    Rosamillia, M
    Chadburn, A
    MODERN PATHOLOGY, 2001, 14 (01) : 159A - 159A
  • [28] Bone marrow biopsy (BM) morphology in patients with chronic myeloid leukemia (CML) treated with STI571
    Chiu, A
    Silver, R
    Rosamillia, M
    Chadburn, A
    LABORATORY INVESTIGATION, 2001, 81 (01) : 159A - 159A
  • [29] Imatinib mesylate (STI571) decreases the vascular endothelial growth factor plasma concentration in patients with chronic myeloid leukemia
    Legros, L
    Bourcier, C
    Jacquel, A
    Mahon, FX
    Cassuto, JP
    Auberger, P
    Pagès, G
    BLOOD, 2004, 104 (02) : 495 - 501
  • [30] Reversal of bone marrow angiogenesis in chronic myeloid leukemia following imatinib mesylate (STI571) therapy
    Kvasnicka, HM
    Thiele, J
    Staib, P
    Schmitt-Graeff, A
    Griesshammer, M
    Klose, J
    Engels, K
    Kriener, S
    BLOOD, 2004, 103 (09) : 3549 - 3551
12345